Medivation rises on upbeat Xtandi urologist survey

Medivation (MDVN +2.9%) is trading notably higher in early action.

The move looks to be attributable to a UBS urologist survey.

From the note: "Xtandi's safety profile is closer to other drugs commonly prescribed by urologists ... suggesting they may favor it vs. Johnson & Johnson's (JNJ) Zytiga."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs